KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Operating Expenses (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Operating Expenses data on record, last reported at $194.5 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 19.68% year-over-year to $194.5 million; the TTM value through Dec 2025 reached $707.2 million, down 8.67%, while the annual FY2025 figure was $707.2 million, 8.67% down from the prior year.
  • Operating Expenses reached $194.5 million in Q4 2025 per PCRX's latest filing, up from $173.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $308.1 million in Q3 2024 and bottomed at $96.3 million in Q3 2021.
  • Average Operating Expenses over 5 years is $156.4 million, with a median of $151.8 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: surged 110.73% in 2024, then crashed 43.8% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $155.0 million in 2021, then grew by 17.33% to $181.8 million in 2022, then dropped by 18.57% to $148.1 million in 2023, then grew by 9.77% to $162.5 million in 2024, then increased by 19.68% to $194.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $194.5 million in Q4 2025, $173.2 million in Q3 2025, and $172.6 million in Q2 2025.